Baxter International Inc vs CAVA Group Inc — how do they compare? Baxter International Inc trades at $25.28 (market cap $13.07B), while CAVA Group Inc trades at $57.25 (market cap $6.69B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.16% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Baxter International Inc for 73 Days and CAVA Group Inc for 8 Days on average.
| BAX | CAVA | |
|---|---|---|
Market Cap | $13.07B | $6.69B |
Volume | 4,406,363 | 4,243,751 |
Sector | Health | Consumer Cyclical |
52-Week High | $28.35 | $97.39 |
52-Week Low | $15.80 | $43.59 |
Typical Hold Time | 73 Days | 8 Days |
Enterprise Value | $20.59B | $6.77B |
Dividend Yield | 0.16% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $25.28, down 1.86% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows mixed fundamentals with recent earnings beats but negative profit margins and elevated P/E ratio of 87.85. Recent developments include a new CFO appointment and positive Q2 2026 results that prompted raised full-year guidance.
The outlook remains cautious as Baxter navigates margin pressures and restructuring efforts. While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE and net income. Analyst consensus leans neutral with a $23.60 price target below current levels, indicating limited upside potential amid ongoing operational headwinds.
CAVA stock trades at $57.25, up 3.34% with strong technical momentum above key support levels. The company demonstrates robust revenue growth with $1.18B in 2025 sales and consistent earnings beats, though valuation remains elevated with a P/E of 102.23. Recent expansion to 500 restaurants and a $100M share repurchase program signal management confidence in growth trajectory.
CAVA presents a compelling growth story with aggressive expansion plans targeting 1,000+ stores by 2032, but faces risks from high valuation, competitive pressures, and rising costs. Analyst consensus remains strongly bullish with a $89.21 price target, though investors should monitor execution risks amid sector headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →